Cancer

September 1, 2017

 Natural product-based PD-1 pathway blockade for Human cancer therapy: Lovastatin, a cholesterol lowering drug, decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 1/September, 2017, 10.54 pm

Introduction:What they say:  A recent study from Cell Signalling Section, Division of Immunology, Department of Pathology, Tennis Court Road, University of Cambridge, Cambridge CB2 1QP, UK shows that “Glycogen Synthase […]
August 30, 2017

Natural product-derived CDK4/6 pathway blockade enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing natural products Berberine, Nimbolide, N-Acetyl-cysteine (BNN) and the anticancer drug Doxorubicin(D) inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 31/August/2017, 1.33 am

Introduction:What they say: A recent study from Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands has identified […]
August 29, 2017

Natural product-derived  therapy for enhancing anti-cancer immunity: Dihydroartemisinin (DHA), a derivative of Artemisinin isolated from Artemesia anuua L, decreases the level of LATS1/2 (large tumor suppressor 1 and 2), increases immunogenicity of tumors, enhances anti-tumor immune responses, and inhibits tumor growth via down regulation of its target gene, 30/August/2017, 1.26 am

Introduction: What they say:  A study from the Department of Pharmacology and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA shows that […]
August 29, 2017

Molecular therapy for Metastatic cancers: Ivermectin, the anthelmintic drug, increases the expression of tumor suppressors RECK1 and CADM1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 30/August/2017, 12.50 am

From Significance of the study to Public health relevance: Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more […]